ANI Pharmaceuticals Inc  

(Public, NASDAQ:ANIP)   Watch this stock  
Find more results for NASDAQ:BPAX
50.85
-0.57 (-1.11%)
Real-time:   3:15PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 50.58 - 51.67
52 week 24.24 - 72.61
Open 51.25
Vol / Avg. 111,970.00/259,787.00
Mkt cap 583.26M
P/E 20.13
Div/yield     -
EPS 2.53
Shares 11.41M
Beta 2.53
Inst. own 91%
Aug 3, 2015
Q2 2015 ANI Pharmaceuticals Inc Earnings Release (Estimated) Add to calendar
May 5, 2015
Q1 2015 ANI Pharmaceuticals Inc Earnings Call
May 5, 2015
Q1 2015 ANI Pharmaceuticals Inc Earnings Release
Apr 14, 2015
ANI Pharmaceuticals Inc at Needham Healthcare Conference
Mar 9, 2015
ANI Pharmaceuticals Inc at ROTH Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin 23.24% 51.36%
Operating margin 50.89% 35.74%
EBITD margin - 42.67%
Return on average assets 6.62% 18.65%
Return on average equity 12.25% 31.63%
Employees 92 -
CDP Score - -

Address

210 W Main St
BAUDETTE, MN 56623-2467
United States - Map
+1-218-6343500 (Phone)
+1-218-6343540 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

ANI Pharmaceuticals, Inc. is a specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. In two facilities with combined manufacturing, packaging and laboratory capacity totaling 173, 00 square feet, the Company manufactures oral solid dose products, as well as liquids and topicals, including narcotics. The Company performs contract manufacturing for other pharmaceutical companies. It has launched three products and has 11 products in development. The Company’s targeted areas of product development include narcotics, anti-cancers and hormones (potent compounds), and extended release niche generic product opportunities. The Company is positioned to develop and manufacture niche oncolytic (anti-cancer) drugs due to the capabilities of the Company's containment facility and its expertise in manufacturing segregation.

Officers and directors

Robert E. Brown Jr. Chairman of the Board
Age: 63
Bio & Compensation  - Reuters
Arthur S. Przybyl President, Chief Executive Officer, Director
Age: 57
Bio & Compensation  - Reuters
Charlotte C. Arnold Chief Financial Officer, Vice President
Age: 51
Bio & Compensation  - Reuters
James G. Marken Vice President - Operations
Age: 51
Bio & Compensation  - Reuters
David J. Sullivan Ph.D. Vice President - Quality Operations
Bio & Compensation  - Reuters
Robert W. Schrepfer Vice President - New Business Development and Contract Manufacturing
Age: 42
Bio & Compensation  - Reuters
Thomas A. Penn Director
Age: 68
Bio & Compensation  - Reuters
Fred H. Holubow Independent Director
Age: 75
Bio & Compensation  - Reuters
Tracy L. Marshbanks Ph.D. Independent Director
Age: 50
Bio & Compensation  - Reuters
Daniel Raynor Independent Director
Age: 54
Bio & Compensation  - Reuters